Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals Inc. (IONS)
:IONS
IONS Analyst Ratings
Strong Buy
17 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IONS Stock 12 Month Forecast
Average Price Target
$81.47
▲(10.77% Upside)
| Highest Price Target$100.00 | Average Price Target$81.47 | Lowest Price Target$46.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$94
Buy
27.80%
Upside
Reiterated
11/10/25
Bernstein
$50→$65
Hold
-11.62%
Downside
Reiterated
11/10/25
H.C. Wainwright
$100→$110
Buy
49.56%
Upside
Reiterated
11/10/25
J.P. Morgan
―
Buy
―
Reiterated
11/09/25
William Blair
―
Buy
―
Reiterated
11/08/25
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Immunocore Holdings (NASDAQ: IMCR)We view updated CORE data presented at AHA as groundbreaking, with clear demonstrations of reduced pancreatitis risk across both the overall sHTG populations (85% risk reduction) and subgroup at highest risk (83% risk reduction). Moreover, treatment with olezarsen demonstrated near-immediate protection from AP events. We believe these data indicate that availability of olezarsen for sHTG will likely be transformational for the treatment of sHTG across a broad spectrum of patients. With a clear and immediate reduction in risk of acute pancreatitis events in the overall population, the data should help support broad olezarsen prescribing and payer coverage across all sHTG patients with serum triglycerides >500 mg/dL, rather than restricting the market to a smaller group of patients with higher triglycerides and a prior AP event.
TD Cowen
$99
Buy
34.60%
Upside
Reiterated
11/07/25
Piper Sandler
$70→$77
Buy
4.69%
Upside
Reiterated
11/04/25
Barclays
$80→$95
Buy
29.16%
Upside
Reiterated
10/30/25
Needham
$78→$90
Buy
22.37%
Upside
Reiterated
10/29/25
Ionis Pharmaceuticals: Strong Financial Performance and Positive Outlook Justify Buy Rating7:40 PM 2025 PRICE TARGET & ESTIMATE CHANGE Biotechnology Ionis Pharmaceuticals, Inc. (IONS) RATING BUY PRICE TARGET $90.00 from $78.00 PREV CLOSE $73.57 52-WEEK RANGE $23.95 - $74.42 3Q25: Guidance Raised. PT to $90.
Bank of America Securities
$83→$86
Buy
16.93%
Upside
Reiterated
10/29/25
RBC Capital
$80→$82
Buy
11.49%
Upside
Reiterated
10/29/25
Oppenheimer
$90
Buy
22.37%
Upside
Reiterated
10/27/25
Raymond James
$75→$85
Buy
15.57%
Upside
Reiterated
10/09/25
Stifel Nicolaus
$43→$67
Hold
-8.91%
Downside
Reiterated
10/06/25
Goldman Sachs
$45→$65
Hold
-11.62%
Downside
Upgraded
09/26/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$94
Buy
27.80%
Upside
Reiterated
11/10/25
Bernstein
$50→$65
Hold
-11.62%
Downside
Reiterated
11/10/25
H.C. Wainwright
$100→$110
Buy
49.56%
Upside
Reiterated
11/10/25
J.P. Morgan
―
Buy
―
Reiterated
11/09/25
William Blair
―
Buy
―
Reiterated
11/08/25
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS) and Immunocore Holdings (NASDAQ: IMCR)We view updated CORE data presented at AHA as groundbreaking, with clear demonstrations of reduced pancreatitis risk across both the overall sHTG populations (85% risk reduction) and subgroup at highest risk (83% risk reduction). Moreover, treatment with olezarsen demonstrated near-immediate protection from AP events. We believe these data indicate that availability of olezarsen for sHTG will likely be transformational for the treatment of sHTG across a broad spectrum of patients. With a clear and immediate reduction in risk of acute pancreatitis events in the overall population, the data should help support broad olezarsen prescribing and payer coverage across all sHTG patients with serum triglycerides >500 mg/dL, rather than restricting the market to a smaller group of patients with higher triglycerides and a prior AP event.
TD Cowen
$99
Buy
34.60%
Upside
Reiterated
11/07/25
Piper Sandler
$70→$77
Buy
4.69%
Upside
Reiterated
11/04/25
Barclays
$80→$95
Buy
29.16%
Upside
Reiterated
10/30/25
Needham
$78→$90
Buy
22.37%
Upside
Reiterated
10/29/25
Ionis Pharmaceuticals: Strong Financial Performance and Positive Outlook Justify Buy Rating7:40 PM 2025 PRICE TARGET & ESTIMATE CHANGE Biotechnology Ionis Pharmaceuticals, Inc. (IONS) RATING BUY PRICE TARGET $90.00 from $78.00 PREV CLOSE $73.57 52-WEEK RANGE $23.95 - $74.42 3Q25: Guidance Raised. PT to $90.
Bank of America Securities
$83→$86
Buy
16.93%
Upside
Reiterated
10/29/25
RBC Capital
$80→$82
Buy
11.49%
Upside
Reiterated
10/29/25
Oppenheimer
$90
Buy
22.37%
Upside
Reiterated
10/27/25
Raymond James
$75→$85
Buy
15.57%
Upside
Reiterated
10/09/25
Stifel Nicolaus
$43→$67
Hold
-8.91%
Downside
Reiterated
10/06/25
Goldman Sachs
$45→$65
Hold
-11.62%
Downside
Upgraded
09/26/25
Best Analysts Covering Ionis Pharmaceuticals
1 Month
xxx
Success Rate
15/22 ratings generated profit
Average Return
+4.71%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 68.18% of your transactions generating a profit, with an average return of +4.71% per trade.
3 Months
xxx
Success Rate
14/22 ratings generated profit
Average Return
+12.88%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +12.88% per trade.
1 Year
Success Rate
18/22 ratings generated profit
Average Return
+34.70%
reiterated a buy rating last month
Copying Gary Nachman's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +34.70% per trade.
2 Years
xxx
Success Rate
33/34 ratings generated profit
Average Return
+43.10%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 97.06% of your transactions generating a profit, with an average return of +43.10% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IONS Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
13
12
15
10
4
Buy
16
25
44
56
47
Hold
21
17
23
23
14
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
50
54
83
90
66
Each month's total comprises the sum of three months' worth of ratings.
IONS Financial Forecast
IONS Stock Forecast FAQ
What is IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals Inc.’s 12-month average price target is 81.47.
What is IONS’s upside potential, based on the analysts’ average price target?
Ionis Pharmaceuticals Inc. has 10.77% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IONS a Buy, Sell or Hold?
Ionis Pharmaceuticals Inc. has a consensus rating of Strong Buy which is based on 17 buy ratings, 4 hold ratings and 0 sell ratings.
What is Ionis Pharmaceuticals Inc.’s price target?
The average price target for Ionis Pharmaceuticals Inc. is 81.47. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $100.00 ,the lowest forecast is $46.00. The average price target represents 10.77% Increase from the current price of $73.55.
The highest analyst price target is $100.00 ,the lowest forecast is $46.00. The average price target represents 10.77% Increase from the current price of $73.55.
What do analysts say about Ionis Pharmaceuticals Inc.?
Ionis Pharmaceuticals Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
How can I buy shares of IONS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.